Latest News
-
Atlas Molecular Pharma receives approval by the European Commission of an Orphan Medicinal Product for the treatment of Congenital Erythropoietic Porphyria GalleryAtlas Molecular Pharma receives approval by the European Commission of an Orphan Medicinal Product for the treatment of Congenital Erythropoietic Porphyria
Atlas Molecular Pharma receives approval by the European Commission of an Orphan Medicinal Product for the treatment of Congenital Erythropoietic Porphyria
DERIO, Spain.- Atlas Molecular Pharma, a private company founded in 2015 in Derio (Spain) as a spin-off from the Centre for Co-operative Research in Biosciences (CIC bioGUNE), announced today the confirmation and approval by the European Commission [...]
-
La EMA (Agencia Europea del Medicamento) se pronuncia favorablemente sobre la designación de fármaco huérfano a una molécula con actividad frente a la Porfíria Eritropoyética Congénita, desarrollada por CIC bioGUNE y ATLAS Molecular Pharma GalleryLa EMA (Agencia Europea del Medicamento) se pronuncia favorablemente sobre la designación de fármaco huérfano a una molécula con actividad frente a la Porfíria Eritropoyética Congénita, desarrollada por CIC bioGUNE y ATLAS Molecular Pharma
La EMA (Agencia Europea del Medicamento) se pronuncia favorablemente sobre la designación de fármaco huérfano a una molécula con actividad frente a la Porfíria Eritropoyética Congénita, desarrollada por CIC bioGUNE y ATLAS Molecular Pharma
El Comité para la designación de medicamentos huérfanos (COMP) de la Agencia Europea del Medicamento (EMA) comunica a la compañía vasca Atlas Molecular Pharma S. L. su opinión favorable a la solicitud del fármaco L2.7.D7 [...]
Atlas Molecular Pharma Receives European Medicines Agency (EMA) Orphan Designation for Congenital Erythropoietic Porphyria
DERIO, Spain.- Atlas Molecular Pharma, a private company founded in 2015 in Derio (Spain) as a spin-off from the Centre for Co-operative Research in Biosciences (CIC bioGUNE), announced today a favourable report, as Orphan Medicinal Product, [...]
ATLAS Molecular Pharma has been awarded with one of the prestigious NEOTEC grants (2016 call)
ATLAS Molecular Pharma succeeded with the competitive NEOTEC call (CDTI), obtaining a grant for a total amount of 213.000 EUR during the period 2017-2018. The NEOTEC Program aims to support the creation and consolidation of [...]